Antibody-targeted chemotherapy with gemtuzumab ozogamicin 
INTRODUCTION
Antibody-targeted chemotherapy is a therapeutic strategy that involves the use of a cytotoxic agent chemically linked to a monoclonal antibody (mAb) that specifically recognizes a tumor-associated antigen. The mAb specifically delivers the cytotoxic agent to tumor cells that express the tumor-associated antigen. The efficacy of antibody-targeted chemotherapy relies heavily on the specific binding of the targeting mAb-drug conjugate to the tumor antigen and on the internalization of the antigen-mAb complex to ensure focused delivery of the conjugated cytotoxic agent inside tumor cells.
Such focused delivery of the cytotoxic agent to tumor cells maximizes its anti-tumor effect and minimizes its normal tissue exposure resulting in an improved therapeutic index. The concept of antibody-targeted chemotherapy is not novel and has been explored extensively with significant preclinical success.
1,2 However, it had not been successfully translated into clinical benefit until the recent introduction of gemtuzumab ozogamicin (Mylotarg® or CMA-676), the first antibody -targeted chemotherapeutic. [3] [4] [5] [6] Presently, gemtuzumab ozogamicin remains the only antibody-targeted chemotherapeutic agent approved for clinical use in the US. 3 Gemtuzumab ozogamicin is comprised of a humanized IgG4 anti-CD33 antibody covalently linked to N-acetyl gamma calicheamicin dimethyl hydrazide (hereafter referred to as CalichDMH), a derivative of gamma calicheamicin, via an acidhydrolysable AcBut linker. [5] [6] [7] [8] Gamma calicheamicin is a potent cytotoxic anti-tumor antibiotic that binds DNA in the minor groove and undergoes thiol-dependent structural changes in its enediyne moiety to generate a di-radical which abstracts hydrogens from the phosphodiester backbone of DNA. This causes double-strand DNA breaks resulting in apoptotic cell death . 9-11 Gemtuzumab ozogamicin binds CD33 on the surface of myeloid cells and is rapidly internalized into lysosomal vesicles whose acidic pH facilitates hydrolysis of the hydrazone functional group within the AcBut linker liberating CalichDMH. [5] [6] [7] [8] Gemtuzumab ozogamicin is indicated for the treatment of elderly ( 60 years of age) acute myeloid leukemia (AML) patients in first relapse who are not candidates for other therapies. 3, 12 Its effectiveness in patients with AML can be attributed to the preferential delivery of CalichDMH to CD33 + myeloid leukemic cells
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From resulting in their elimination. [5] [6] [7] [8] CD33, the molecular target of gemtuzumab ozogamicin, is a cell-surface antigen whose expression is confined to the myeloid lineage. CD33 is expressed by both normal and malignant myeloid cells but is not expressed by nonhematopoietic lineages or stem cell precursors of the myeloid lineage. 13 The clinical effectiveness of gemtuzumab ozogamicin provides a strong rationale for applying the antibody-targeted calicheamicin strategy to other malignancies using target antigens with similar lineage-confined expression.
CD22 is an attractive target for antibody-targeted chemotherapy and has been extensively explored as a target for immunotoxin-based therapeutic strategies. [14] [15] [16] CD22 is a terminal 2,6-linked sialic acid-binding cellular lectin and a member of the Ig superfamily.
17
CD22 is expressed on the surface of mature B-lymphocytes and their malignant counterparts but not on other non-B lineages including hematopoietic stem cells .
17-21
CD22 is rapidly internalized upon binding to anti-CD22 mAb. 22, 23 These properties make CD22 a suitable molecular target for antibody -targeted calicheamicin therapy for B lymphoid malignancies. Using a humanized anti-CD22 mAb (G5/44), we have created a CD22-targeted immunoconjugate of CalichDMH, designated as CMC-544. The present study describes the functional characterization of CMC-544 and provides evidence of its strong preclinical anti-tumor activity against human B-cell lymphoma (BCL) cell lines, both in vitro and in vivo. This study supports the evaluation of CMC-544 as an effective therapeutic option for patients with BCLs, especially nonHodgkin's lymphoma.
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From with the HBS buffer over a 15 min period. The antigenic surface was regenerated by washing the biosensor chip with 15 µl of the regeneration buffer (10 mM NaOH and 200 mM NaCl) for 30 s, followed by a stabilization time of 2 min before the next cycle.
Kinetic constants were calculated by nonlinear least square regression analysis using a 1:1 Langmuir binding curve fitting model and BIAevaluation program (version 3.0, BIAcore).
26

Cytotoxicity assays
Various BCL cells were cultured in the presence of various concentrations of unconjugated CalichDMH, unconjugated antibody (G5/44), CMC-544 or CMA-676 for 96 hr after which cell viability was measured by propidium iodide exclusion and analyzed by flow cytometry using a Becton Dickinson FACSort. Red fluorescent intensity (emission at 617 nm in the FL2 channel) of the cells excited at 488 nm was measured.
The regions for viable cells were also set using both the forward light scatter and right- 
Subcutaneous xenografts
Female, athymic nude mice were exposed to total body irradiation (400 rads) to further suppress their residual immune system and facilitate the establishment of BCL xenografts. Three days later, the irradiated mice were injected subcutaneously (SC) based on the quantity of CalichDMH. In additional studies, the effect of CMC-544 or G5/44 on the development of the BCL was also examined. In these studies, treatments
were administered 3 days after the BCL were injected SC. Tumors were measured at least once a week and their mass was defined as tumor mass (g) = 0. . Serum concentrations of CMC-544 were quantified using a modification of an enzyme-linked immunosorbent assay (ELISA) originally developed for the pharmacokinetic measurements of CMA-676. 27 A soluble form of the CD22 protein, CD22mFc, was immobilized on microtiter plates to capture the G5/44 antibody portion within CMC-544. The CalichDMH portion of the molecule was then recognized with a rabbit anti-calicheamicin antibody. A goat anti-rabbit antibody conjugated to horseradish peroxidase was used to detect the bound rabbit antibody using 3,3', 5,5' tetramethylbenzidine (TMB) as a substrate for colorimetric readout. CMC-544 diluted in nude mouse serum was used as a standard in these determinations. The pharmacokinetic parameters for each dose group were estimated using the pharmacokinetic and statistical analysis software, IBIS (version 1.5.0) that runs under SAS (version 6.12). Calculations were performed using a model-independent approach as described by Gibaldi and Perrier. 28 Briefly, C max and t max values were taken directly from the observed mean data. The area under the serum concentration versus time curve (AUC) over the sampling period of 336 hours and its standard error were calculated using a method described by French and Powers 29 that is based upon a rearrangement of the linear trapezoidal rule.
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RESULTS
Binding of CMC-544 to CD22
The binding of CMC-544 to human CD22 was evaluated by surface plasmon resonance analysis using CD22mFc covalently immobilized on a biosensor chip. The 
In Vitro effects of CMC-544 against human B lymphoma cells
The effect of CMC-544 on the in vitro growth of various CD22 + B lymphoma cell lines was determined. CD33-targeted CMA-676 was used as an isotype-matched nonbinding control conjugate to explore antigen-nonspecific effects of the conjugates.
CalichDMH was also included for comparison in these studies. The use of unconjugated CalichDMH indicated sensitivity of each cell line to this drug. Table 1 shows results of the cytotoxic effect (IC 50 based on the CalichDMH equivalents defined CMA-676 (isotype-matched non-binding control conjugate), at 160 µg/kg (administered IP Q4Dx3) had no significant effect on the growth of Ramos BCL xenografts.
The ability of CMC-544 to inhibit the establishment of developing Ramos BCL xenografts was examined. Ramos cells were injected SC and 3 days later IP treatment
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CMC-544 completely suppressed the establishment of the developing Ramos BCL ( Figure 4A ). The effect of CMC-544 was also studied with large (almost 10% of the body weight) Ramos BCL xenografts. Ramos xenografts were staged at 2 g of tumor mass after which treatment with CMC-544 was initiated. CMA-676 was again used as a negative control conjugate. In the CMA-676 treatment group, the tumors grew rapidly and within less than 2-weeks post-initiation of therapy, these mice had to be euthanized. In contrast, similar treatment with CMC-544 caused almost complete regression of lymphoma xenografts ( Figure 4B ). Monitoring Large RL BCL xenografts, which had grown in spite of the high dose treatment with unconjugated G5/44, were further treated with CMC-544 and regressed in response to the CMC-544 treatment ( Figure 6B) .
Thus in the absence of CalichDMH, the unconjugated anti-CD22 mAb G5/44 had no impact on the growth of BCL xenografts and these G5/44-treated BCLs were still susceptible to CMC -544.
Pharmacokinetics of CMC-544 in nude mice
To determine the serum levels of CMC-544 that were associated with the antitumor effects described above, tumor-bearing (SC RL B lymphoma) or non-tumorbearing nude mice received a single dose of CMC-544 IP at 160 µg of conjugated CalichDMH/kg and serum samples from these mice were assayed for the presence of CMC-544 using an enzyme-linked immunoassay. The immunoassay was specifically designed and validated to detect antibody conjugates of CalichDMH. 27 As shown in (Table 2) Collectively, these results suggest that CMC-544 not only prevents the establishment of subcutaneous BCL xenografts but also causes regression of established BCL xenografts at doses lower than its maximum nonlethal dose.
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